Purchase this article with an account.
Efrain Romo-Garcia, David Magana-Garcia, Mariana Gonzalez-Reyes, Tania Nieblas-Aguilar, Sergio Sital-Gastelum; Is Hyperbaric Oxygen Useful in the Treatment of Diabetic Macular Edema?. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1754.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the use of hyperbaric oxygen in conbination with bevacizumab and bevacizumab alone when treating diabetic macular edema.
In this pilot study, patients diagnosed with non-proliferative diabetic retinopathy and diabetic macular edema in age range 40-85 years old were randomized into 2 groups. Control group were treated with intravitreal bevacizumab and study group in addition to intravitreal bevacizumab received hyperbaric oxygen therapy. A complete ophthalmological examination was perform at baseline, 1 week, 1 month and 3 months; FA and macular SD-OCT were recorded at baseline and monthly.
Data show that hyperbaric oxygen is an effective adjuvant to bevacizumab in the treatment of diabetic macular edema. Both groups show improvement of macular edema and visual acuity. The group with combine theraphy showed better results when comparing to control group. The reduction of the macular edema seems to last longer in the study group as documented on FA and SD-OCT.
Our results suggest that the coadjuvant use of hyperbaric oxygen in addition to the antiangiogenic effect of intravitreal bevacizumab, could be beneficial in the treatment of diabetic macular edema. Long-term follow up and better study desings are needed for a better understanding of this combination theraphy.
This PDF is available to Subscribers Only